IMFINZI (durvalumab)
ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·BILIARY TRACT MALIGNANCY·+10
AstraZeneca Pharmaceuticals
Indication
Non-muscle invasive bladder cancer
Non-muscle invasive bladder cancer is an epithelial malignancy of the urinary tract characterized by neoplastic urothelial cells confined to the inner mucosal lining or the underlying subepithelial connective tissue of the bladder wall without invasion into the detrusor muscle. Read more about Non-muscle invasive bladder cancer
2 drugs 2 manufacturers
Drugs that treat it
Common Non-muscle invasive bladder cancer therapies.
ZUSDURI (mitomycin)
NON-MUSCLE INVASIVE BLADDER CANCER
UROGEN PHARMA
Filter & compare in the drug finder →Opens the drug finder with Non-muscle invasive bladder cancer preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonNon-muscle invasive bladder cancer is an epithelial malignancy of the urinary tract characterized by neoplastic urothelial cells confined to the inner mucosal lining or the underlying subepithelial connective tissue of the bladder wall without invasion into the detrusor muscle.
Predominantly affecting adults and representing the majority of newly diagnosed bladder cancers, it manifests histopathologically as non-invasive papillary urothelial carcinoma (stage Ta), carcinoma in situ (stage Tis), or lamina propria-invasive disease (stage T1).
Clinically, it most frequently presents with painless gross or microscopic hematuria, accompanied by irritative voiding symptoms in some cases, and is marked by high rates of local recurrence and a variable risk of progression to muscle invasion.
- cancer.gov
Non-muscle invasive bladder cancer is an epithelial malignancy of the urinary tract characterized by neoplastic urothelial cells confined to the inner mucosal lining or the underlying subepithelial connective tissue of the bladder wall without invasion into the detrusor muscle
- mayoclinic.org
Non-muscle invasive bladder cancer is an epithelial malignancy of the urinary tract characterized by neoplastic urothelial cells confined to the inner mucosal lining or the underlying subepithelial connective tissue of the bladder wall without invasion into the detrusor muscle Predominantly affecting adults and representing the majority of newly diagnosed bladder cancers, it manifests histopathologically as non-invasive papillary urothelial carcinoma (stage Ta), carcinoma in situ (stage Tis), or...
- nih.gov
Predominantly affecting adults and representing the majority of newly diagnosed bladder cancers, it manifests histopathologically as non-invasive papillary urothelial carcinoma (stage Ta), carcinoma in situ (stage Tis), or lamina propria-invasive disease (stage T1)
- nih.gov
Clinically, it most frequently presents with painless gross or microscopic hematuria, accompanied by irritative voiding symptoms in some cases, and is marked by high rates of local recurrence and a variable risk of progression to muscle invasion
- tnvalleyurology.com
Clinically, it most frequently presents with painless gross or microscopic hematuria, accompanied by irritative voiding symptoms in some cases, and is marked by high rates of local recurrence and a variable risk of progression to muscle invasion
Personalize your experience
Follow Non-muscle invasive bladder cancer and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.